Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

被引：0
|
作者：
Laura Obici
Senda Ajroud-Driss
Kon-Ping Lin
John L. Berk
Julian D. Gillmore
Parag Kale
Haruki Koike
David Danese
Emre Aldinc
Chongshu Chen
John Vest
David Adams
机构：
[1] IRCCS Fondazione Policlinico San Matteo,Amyloidosis Research and Treatment Centre
[2] Northwestern University Feinberg School of Medicine,Department of Neurology
[3] Taipei Veterans General Hospital,Department of Neurology
[4] Boston Medical Center,National Amyloidosis Centre, Royal Free Hospital
[5] University College London,Department of Neurology
[6] Baylor University Medical Center,Neurology Department
[7] Nagoya University Graduate School of Medicine,undefined
[8] Alnylam Pharmaceuticals,undefined
[9] Université Paris-Saclay,undefined
[10] U1195,undefined
[11] INSERM,undefined
[12] AP-HP,undefined
[13] CHU Bicêtre,undefined
来源：
Neurology and Therapy | 2023年 / 12卷 / 5期
关键词：
ATTRv amyloidosis; hATTR amyloidosis; Nutritional status; Physical function; Polyneuropathy; Quality of life; RNA interference; Vutrisiran;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1759 / 1775
页数：16
相关论文
共 50 条
  • [31] Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) : 95 - 99
  • [32] Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis
    Antunes, Bernardo
    Conceicao, Isabel
    de Campos, Catarina Falcao
    de Carvalho, Mamede
    NEUROLOGICAL SCIENCES, 2025, 46 (02) : 929 - 934
  • [33] Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gorevic, Peter
    Franklin, Jaclyn
    Chen, Jihong
    Sajeev, Gautam
    Wang, Jessie C. H.
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (01) : 121 - 129
  • [34] LONG-TERM, INTEGRATED CARDIAC SAFETY OF PATISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Dispenzieri, Angela
    Gillmore, Julian
    Polydefkis, Michael
    Plante-Bordeneuve, Violaine
    Schmidt, Hartmut
    Berber, Erhan
    Wang, Jing Jing
    Sweetser, Marianne
    White, Matthew
    Maurer, Mathew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 690 - 690
  • [35] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
    Gonzalez-Duarte, Alejandra
    Judge, Daniel P.
    Dispenzieri, Angela
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Polydefkis, Michael
    NEUROLOGY, 2020, 94 (15)
  • [36] Impact of Patisiran, an RNAi Therapeutic, on Diarrhea Symptoms in Patients With Hereditary Transthyretin-Mediated Amyloidosis
    Obici, Laura
    Gonzalez-Duarte, Alejandra
    Waddington-Cruz, Marcia
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Ueda, Mitsuharu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1657 - S1657
  • [37] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
    Judge, Daniel P.
    Gonzalez-Duarte, Alejandra
    Dispenzieri, Angela
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Polydefkis, Michael
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S78 - S78
  • [38] HELIOS-A: 9-month subgroup analyses and exploratory efficacy results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Remiche, Gauthier
    Adams, David
    Taylor, Mark S.
    Plante-Bordeneuve, Violaine
    Berk, John L.
    Gonzales-Duarte, Alejandra
    Gillmore, Julian D.
    Low, Soon Chai
    Sekijima, Yoshiki
    Obici, Laura
    Blakesley, Rick
    Arum, Seth
    Shilling, Rebecca
    Vest, John
    Polydefkis, Michael
    ACTA CARDIOLOGICA, 2022, 77 : 14 - 14
  • [39] An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Plante-Bordeneuve, Violaine
    Lin, Hollis
    Gollob, Jared
    Agarwal, Sonalee
    Betts, Marissa
    Fahrbach, Kyle
    Chitnis, Madhura
    Polydefkis, Michael
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (04) : 473 - 481
  • [40] Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Labeyrie, Celine
    Merkel, Madeline
    Sethi, Sakshi
    Popadic, Lyuba
    Yang, Hongbo
    Sweetser, Marianne T.
    Lin, Hollis
    Adams, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
12345